-
公开(公告)号：US10106501B2
公开(公告)日：2018-10-23
申请号：US15176309
申请日：2016-06-08
Applicant: AbbVie Inc.
Inventor： Maria A. Argiriadi , Eric C. Breinlinger , Kevin P. Cusack , Adrian D. Hobson , Dominique Potin , Martine Barth , Jerome Amaudrut , Olivia Poupardin , Laurent Mounier , Michael E. Kort
IPC: C07D209/08 , C07D401/10 , C07D403/10 , C07D401/14 , C07D405/12 , C07D401/06 , C07D491/107 , C07D405/14 , C07D235/06 , C07D471/04 , C07D487/04 , C07D231/56 , C07D235/16 , C07D405/10 , C07D491/10 , C07D209/14 , C07D209/18
Abstract: The invention provides compounds of Formula (I) pharmaceutically acceptable salts, thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological conditions.
-
公开(公告)号：US09751850B2
公开(公告)日：2017-09-05
申请号：US14532573
申请日：2014-11-04
Applicant: AbbVie Inc.
Inventor： Richard J. Perner , Michael E. Kort , Stanley DiDomenico , Jun Chen , Anil Vasudevan
IPC: A61K31/44 , A61K45/06 , A61K31/381 , C07D333/22 , C07D213/53 , C07D215/12 , C07D217/14 , C07D333/20 , A61K31/47 , A61K31/472 , C07D213/61 , C07D213/64
CPC classification number: C07D333/22 , A61K31/381 , A61K31/44 , A61K31/47 , A61K31/472 , A61K45/06 , C07D213/53 , C07D213/61 , C07D213/64 , C07D215/12 , C07D217/14 , C07D333/20
Abstract: Compounds of formula (I) wherein R1, R2, R3, and Y are defined in the description are TRPA1 antagonists. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also disclosed.
-
公开(公告)号：US08796328B2
公开(公告)日：2014-08-05
申请号：US13922442
申请日：2013-06-20
Applicant: AbbVie Inc.
Inventor： Arthur Gomtsyan , Jerome Daanen , Michael E. Kort , Philip R. Kym , Eric A. Voight , Kevin R. Woller
CPC classification number: C07C317/28 , A61K31/18 , A61K31/192 , A61K31/352 , A61K31/353 , A61K31/436 , C07C311/08 , C07C2602/08 , C07D263/48 , C07D311/68 , C07D311/96 , C07D401/04 , C07D417/12 , C07D491/052
Abstract: Disclosed herein are compounds of formula (I) or pharmaceutically acceptable salts, prodrugs, or combinations thereof, wherein X1, L, Rx, Ry, Rz, R1, R2, A, m, n, p, q, and r are defined in the specification. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also disclosed.
Abstract translation: 本文公开了式（I）化合物或其药学上可接受的盐，前药或其组合，其中X1，L，Rx，Ry，Rz，R1，R2，A，m，n，p，q和r定义在 规格。 还公开了包含这些化合物的组合物和使用这些化合物和组合物治疗病症和病症的方法。
-
公开(公告)号：US20230066771A1
公开(公告)日：2023-03-02
申请号：US17443264
申请日：2021-07-23
Applicant: AbbVie Inc.
Inventor： Maria A. Argiriadi , Eric C. Breinlinger , Kevin P. Cusack , Adrian D. Hobson , Dominique Potin , Martine Barth , Jerome Amaudrut , Olivia Poupardin , Laurent Mounier , Michael E. Kort
IPC: C07D209/08 , C07D401/10 , C07D403/10 , C07D401/14 , C07D405/12 , C07D401/06 , C07D491/107 , C07D405/14 , C07D235/06 , C07D471/04 , C07D487/04 , C07D231/56 , C07D235/16 , C07D405/10 , C07D491/10 , C07D209/14 , C07D209/18
Abstract: The invention provides compounds of Formula (I) pharmaceutically acceptable salts, thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological conditions.
-
5.发明申请6-HETEROARYLOXY- OR 6-ARYLOXY-QUINOLINE-2-CARBOXAMIDES AND METHOD OF USE 有权6-异亮氨酸或6-芳基喹啉-2-羧酸酰胺及其使用方法公开(公告)号：US20160355482A1
公开(公告)日：2016-12-08
申请号：US15239554
申请日：2016-08-17
Applicant: AbbVie Inc.
Inventor： Andrew Bogdan , Marlon D. Cowart , David A. DeGoey , Tammie K. Jinkerson , John R. Koenig , Michael E. Kort , Bo Liu , Mark A. Matulenko , Derek W. Nelson , Meena V. Patel , Hillary Peltier , Marc J. Scanio , Brian D. Wakefield
IPC: C07D215/48 , C07D409/14 , C07D487/08 , C07D471/04 , C07D487/04 , C07D405/14 , C07D417/14 , C07D401/12 , C07D401/14
CPC classification number: C07D215/48 , C07D401/12 , C07D401/14 , C07D405/12 , C07D405/14 , C07D409/12 , C07D409/14 , C07D417/12 , C07D417/14 , C07D471/04 , C07D487/04 , C07D487/08
Abstract: Compounds of formula (I) and pharmaceutically acceptable salts, esters, amides, or radiolabelled forms thereof, wherein R1, R2, and R3 are as defined in the specification, are useful in treating conditions or disorders prevented by or ameliorated by voltage-gated sodium channels, e.g., Nav1.7 and/or Nav1.8. Methods for making the compounds are disclosed. Also disclosed are pharmaceutical compositions of compounds of formula (I), and methods for using such compounds and compositions.
Abstract translation: 和其药学上可接受的盐，酯，酰胺或放射性标记形式，其中R1，R2和R3如说明书中所定义，可用于治疗由电压门控钠通道（例如Nav1）预防或改善的病症或病症。 7和/或Nav1.8。 公开了制备化合物的方法。 还公开了式（I）化合物的药物组合物，以及使用这些化合物和组合物的方法。
-
Patent Agency Ranking
公开(公告)号：US20130345255A1
公开(公告)日：2013-12-26
申请号：US13922442
申请日：2013-06-20
Applicant: AbbVie Inc.
Inventor： Arthur Gomtsyan , Jerome Daanen , Michael E. Kort , Philip R. Kym , Eric A. Voight , Kevin R. Woller
IPC: C07C317/28 , A61K31/192 , A61K31/353 , A61K31/436 , A61K31/352 , C07D311/96 , C07D491/052 , A61K31/18 , C07D311/68
CPC classification number: C07C317/28 , A61K31/18 , A61K31/192 , A61K31/352 , A61K31/353 , A61K31/436 , C07C311/08 , C07C2602/08 , C07D263/48 , C07D311/68 , C07D311/96 , C07D401/04 , C07D417/12 , C07D491/052
Abstract: Disclosed herein are compounds of formula (I) or pharmaceutically acceptable salts, prodrugs, or combinations thereof, wherein X1, L, Rx, Ry, Rz, R1, R2, A, m, n, p, q, and r are defined in the specification. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also disclosed.
Abstract translation: 本文公开了式（I）化合物或其药学上可接受的盐，前药或其组合，其中X1，L，Rx，Ry，Rz，R1，R2，A，m，n，p，q和r定义在 规格。 还公开了包含这些化合物的组合物和使用这些化合物和组合物治疗病症和病症的方法。
-
公开(公告)号：US20180334435A1
公开(公告)日：2018-11-22
申请号：US15952682
申请日：2018-04-13
Applicant: AbbVie Inc.
Inventor： Andrew Bogdan , Marlon D. Cowart , David A. DeGoey , Tammie K. Jinkerson , John R. Koenig , Michael E. Kort , Bo Liu , Mark A. Matulenko , Derek W. Nelson , Meena V. Patel , Hillary Peltier , Marc J. Scanio , Brian D. Wakefield
IPC: C07D215/48 , C07D487/04 , C07D405/12 , C07D487/08 , C07D401/12 , C07D471/04 , C07D417/14 , C07D405/14 , C07D409/14 , C07D401/14 , C07D409/12 , C07D417/12
CPC classification number: C07D215/48 , C07D401/12 , C07D401/14 , C07D405/12 , C07D405/14 , C07D409/12 , C07D409/14 , C07D417/12 , C07D417/14 , C07D471/04 , C07D487/04 , C07D487/08
Abstract: Compounds of formula (I) and pharmaceutically acceptable salts, esters, amides, or radiolabelled forms thereof, wherein R1, R2, and R3 are as defined in the specification, are useful in treating conditions or disorders prevented by or ameliorated by voltage-gated sodium channels, e.g., Nav1.7 and/or Nav1.8. Methods for making the compounds are disclosed. Also disclosed are pharmaceutical compositions of compounds of formula (I), and methods for using such compounds and compositions.
-
公开(公告)号：US20170226062A9
公开(公告)日：2017-08-10
申请号：US15239554
申请日：2016-08-17
Applicant: AbbVie Inc.
Inventor： Andrew Bogdan , Marlon D. Cowart , David A. DeGoey , Tammie K. Jinkerson , John R. Koenig , Michael E. Kort , Bo Liu , Mark A. Matulenko , Derek W. Nelson , Meena V. Patel , Hillary Peltier , Marc J. Scanio , Brian D. Wakefield
IPC: C07D215/48 , C07D409/14 , C07D487/08 , C07D471/04 , C07D487/04 , C07D405/14 , C07D417/14 , C07D401/12 , C07D401/14
CPC classification number: C07D215/48 , C07D401/12 , C07D401/14 , C07D405/12 , C07D405/14 , C07D409/12 , C07D409/14 , C07D417/12 , C07D417/14 , C07D471/04 , C07D487/04 , C07D487/08
Abstract: Compounds of formula (I) and pharmaceutically acceptable salts, esters, amides, or radiolabelled forms thereof, wherein R1, R2, and R3 are as defined in the specification, are useful in treating conditions or disorders prevented by or ameliorated by voltage-gated sodium channels, e.g., Nav1.7 and/or Nav1.8. Methods for making the compounds are disclosed. Also disclosed are pharmaceutical compositions of compounds of formula (I), and methods for using such compounds and compositions.
-
公开(公告)号：US20160362370A1
公开(公告)日：2016-12-15
申请号：US15176309
申请日：2016-06-08
Applicant: AbbVie Inc.
Inventor： Maria A. Argiriadi , Eric C. Breinlinger , Kevin P. Cusack , Adrian D. Hobson , Dominique Potin , Martine Barth , Jerome Amaudrut , Olivia Poupardin , Laurent Mounier , Michael E. Kort
IPC: C07D209/08 , C07D403/10 , C07D401/14 , C07D405/12 , C07D231/56 , C07D491/107 , C07D405/14 , C07D235/06 , C07D471/04 , C07D487/04 , C07D401/10 , C07D401/06
CPC classification number: C07D209/08 , C07D209/14 , C07D209/18 , C07D231/56 , C07D235/06 , C07D235/16 , C07D401/06 , C07D401/10 , C07D401/14 , C07D403/10 , C07D405/10 , C07D405/12 , C07D405/14 , C07D471/04 , C07D487/04 , C07D491/10 , C07D491/107
Abstract: The invention provides compounds of Formula (I) pharmaceutically acceptable salts, thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological conditions.
Abstract translation: 其药学上可接受的盐，其中所述变量在本文中定义。 本发明的化合物可用于治疗免疫学病症。
-
公开(公告)号：US09156788B2
公开(公告)日：2015-10-13
申请号：US13761862
申请日：2013-02-07
Applicant: AbbVie Inc.
Inventor： Erol K. Bayburt , Bruce Clapham , Phil B. Cox , Jerome F. Daanen , Arthur Gomtsyan , Michael E. Kort , Philip R. Kym , Eric A. Voight
IPC: A61K31/444 , C07D213/30 , C07D239/26 , C07D401/04 , C07D405/12 , C07D213/50 , C07D401/12
CPC classification number: C07D213/30 , C07D213/50 , C07D239/26 , C07D401/12 , C07D405/12
Abstract: Disclosed herein are modulators of TRPV3 of formula (I) wherein G1, X1, X2, X3, X4, X5, G2, Z1, Ra, Rb, u, and p are as defined in the specification. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also presented.
Abstract translation: 本文公开了式（I）的TRPV3的调节剂，其中G1，X1，X2，X3，X4，X5，G2，Z1，Ra，Rb，u和p如说明书中所定义。 还提出了包含这些化合物的组合物和使用这些化合物和组合物治疗病症和障碍的方法。
-
-
-
-
-
-
-
-
-
Search Results
26
records
(took 0.043 seconds)
